171 related articles for article (PubMed ID: 30182281)
1. International Symposium: Trailblazing in Cancer Immunotherapy, October 29-31, 2017, Pamplona, Spain.
Berraondo P; Aznar MA; Perez-Ruiz E; Rodriguez-Ruiz ME; Castañon E; Perez-Gracia JL; Melero I
Cancer Immunol Immunother; 2018 Nov; 67(11):1809-1813. PubMed ID: 30182281
[No Abstract] [Full Text] [Related]
2. International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010.
Ochoa MC; Hervas-Stubbs S; Palazon A; Martinez-Forero I; Berraondo P; Sarobe P; Melcher A; Melero I
Cancer Immunol Immunother; 2011 May; 60(5):753-6. PubMed ID: 21380561
[No Abstract] [Full Text] [Related]
3. Routing cancer immunology and immunotherapy from the lab to the clinic 4-5 th March 2014, Center for Applied Medical Research and University Clinic, Pamplona, Spain.
Aznar MÁ; Melero I; Quetglas JI
J Transl Med; 2014 Jul; 12():202. PubMed ID: 25060862
[TBL] [Abstract][Full Text] [Related]
4. International Symposium on Immunodiagnosis and Immunotherapy of Cancer, Erfurt, GDR, October 12-16, 1980.
Arch Geschwulstforsch; 1981; 51(6):475-531. PubMed ID: 6120687
[No Abstract] [Full Text] [Related]
5. International symposium on immunodiagnosis and immunotherapy of cancer. October 12-16, 1980, Erfurt, West Germany.
Arch Geschwulstforsch; 1981; 51(4):283-374. PubMed ID: 6119061
[No Abstract] [Full Text] [Related]
6. Third international Dresden symposium on immunotherapy of cancer.
Schmitz M; Bornhauser M; Ockert D; Rieber EP
Cancer Res; 2001 Apr; 61(8):3524-8. PubMed ID: 11309317
[No Abstract] [Full Text] [Related]
7. Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6-8, 2014.
Kloke BP; Mahr A; Jabulowsky RA; Kutscher S; Rae R; Britten CM
Cancer Immunol Immunother; 2015 Jul; 64(7):923-30. PubMed ID: 25548093
[No Abstract] [Full Text] [Related]
8. [Immunotherapy and cancers: last news from the front (Asco 2015)].
Nau JY
Rev Med Suisse; 2015 Jun; 11(480):1410-1. PubMed ID: 26267949
[No Abstract] [Full Text] [Related]
9. [New era of tumor immunotherapy].
Yoshitake Y; Nakatsura T; Nishimura Y
Nihon Rinsho; 2005 Apr; 63 Suppl 4():46-55. PubMed ID: 15861634
[No Abstract] [Full Text] [Related]
10. Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells?
Abken H; Hombach A; Reinhold U; Ferrone S
Immunol Today; 1998 Jan; 19(1):2-5. PubMed ID: 9465480
[No Abstract] [Full Text] [Related]
11. Second meeting of the Spanish Immunotherapy Group GEIT (Grupo Español de Inmunoterapia), January 16, 2015, in Zaragoza, Spain.
Anel A; Martínez-Lostao L; Pardo J
Cancer Immunol Immunother; 2015 Aug; 64(8):1067-9. PubMed ID: 26076665
[No Abstract] [Full Text] [Related]
12. Targeted cytotoxic cells as a novel form of cancer immunotherapy.
Segal DM; Garrido MA; Perez P; Titus JA; Winkler DA; Ring DB; Kaubisch A; Wunderlich JR
Mol Immunol; 1988 Nov; 25(11):1099-103. PubMed ID: 3265476
[No Abstract] [Full Text] [Related]
13. Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop.
Berraondo P; Ochoa MC; Rodriguez-Ruiz ME; Minute L; Lasarte JJ; Melero I
Cancer Res; 2016 May; 76(10):2863-7. PubMed ID: 27308833
[TBL] [Abstract][Full Text] [Related]
14. The role of T lymphocytes in the immunotherapy of tumours.
Brondz BD; Balashov KE
Biomed Sci; 1991; 2(5):441-9. PubMed ID: 1840832
[TBL] [Abstract][Full Text] [Related]
15. 8th Annual Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015--May 20-22, Vancouver, Canada.
Boudreau JE; Wouters MC; Krawczyk CM
Cancer Immunol Immunother; 2016 Feb; 65(2):235-41. PubMed ID: 26759005
[No Abstract] [Full Text] [Related]
16. The use of agonistic anti-CD40 therapy in treatments for cancer.
Khong A; Nelson DJ; Nowak AK; Lake RA; Robinson BW
Int Rev Immunol; 2012 Aug; 31(4):246-66. PubMed ID: 22804570
[TBL] [Abstract][Full Text] [Related]
17. Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer.
Balwit JM; Kalinski P; Sondak VK; Coulie PG; Jaffee EM; Gajewski TF; Marincola FM
J Transl Med; 2011 May; 9():60. PubMed ID: 21569425
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapy--the endgame begins.
Weiner LM
N Engl J Med; 2008 Jun; 358(25):2664-5. PubMed ID: 18565858
[No Abstract] [Full Text] [Related]
19. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
[TBL] [Abstract][Full Text] [Related]
20. Breakthrough of the year 2013. Cancer immunotherapy.
Couzin-Frankel J
Science; 2013 Dec; 342(6165):1432-3. PubMed ID: 24357284
[No Abstract] [Full Text] [Related]
[Next] [New Search]
